医学
内科学
胃肠病学
糖尿病
脂肪肝
随机对照试验
安慰剂
六烯酸
二十碳五烯酸
混淆
2型糖尿病
2型糖尿病
内分泌学
疾病
多不饱和脂肪酸
脂肪酸
病理
替代医学
化学
有机化学
作者
Abbas Ali Sangouni,Zahra Orang,Hassan Mozaffari–Khosravi
出处
期刊:BMC Nutrition
[Springer Nature]
日期:2021-12-15
卷期号:7 (1)
被引量:6
标识
DOI:10.1186/s40795-021-00490-8
摘要
Patients with non-alcoholic fatty liver disease (NAFLD) as well as type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular diseases (CVD). Omega-3 supplementation has been proposed as a possible strategy for management of cardiometabolic risk. Cardiometabolic indices can predict and evaluate the cardiometabolic risk.We investigated the effect of omega-3 supplementation on accurate and available cardiometabolic indices including atherogenic index of plasma (AIP), Castelli risk index I, Castelli risk index II and atherogenic coefficient (AC) in diabetic patients with NAFLD.We conducted a double-blind, randomized controlled trial (RCT) for 12 weeks. From August 2016 to March 2017, the subjects referred to Faghihi hospital in Shiraz, Iran, were recruited. Sixty diabetic patients with NAFLD were randomly assigned into the omega-3 (2000 mg/d omega-3 capsule contained 360 mg/d eicosapentaenoic acid and 240 mg/d docosahexaenoic acid) and the placebo (liquid paraffin) groups using computer-generated random number table.Omega-3 supplementation compared to the placebo had no significant effect on AIP (- 0.11 ± 0.20 vs. -0.03 ± 0.16; P = 0.11), Castelli risk index I (- 0.25 ± 0.6 vs. -0.07 ± 0.7; P = 0.42), Castelli risk index II (- 0.24 ± 0.5 vs. -0.14 ± 0.5; P = 0.63) and AC (- 0.25 ± 0.6 vs. -0.07 ± 0.7; P = 0.42). After adjusting for confounding factors, the findings remained without change.Omega-3 supplementation (2000 mg/d) for 12 weeks has no effect on cardiometabolic risk. It seems, higher doses of omega-3 can improve cordiometabolic risk. The trial was registered at Iranian Registry of Clinical Trials IRCT2016102530489N1.
科研通智能强力驱动
Strongly Powered by AbleSci AI